HOME > ARCHIVE
ARCHIVE
- Taisho Drops 7 of 11 Compounds from Bioventures
July 14, 2003
- CTD Applications Become Obligatory on July 1
July 14, 2003
- Sumitomo to Boost R&D Investment, Build Overseas Marketing Systems
July 14, 2003
- Total Fertility, Natural Increase in Population at Record Lows
July 14, 2003
- Daiichi Suntory Pharma to See Steady Growth After FY2007
July 14, 2003
- REGULATORY NEWS IN BRIEF
July 14, 2003
- Asahi Kasei Reinforces GE Line-up in Major Fields
July 14, 2003
- Aeon Welcia Stores Breaks Off Relations with Drug Eleven
July 14, 2003
- Meet the Leaders (22)
July 7, 2003
- CORPORATE ROUNDUP NEWS IN BRIEF
July 7, 2003
- WORLD NEWS IN BRIEF
July 7, 2003
- NEW PRODUCTS
July 7, 2003
- Sankyo Reports Good Results with e-Promotion
July 7, 2003
- PRESS SEMINAR
July 7, 2003
- FJPWA Study Team Proposes Model PMS Manual
July 7, 2003
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
July 7, 2003
- FPMAJ Answers FJPWA on Bio-derived Product Tracking Cost Sharing
July 7, 2003
- DIAGNOSTIC NEWS IN BRIEF
July 7, 2003
- Acquisition of Uji to Allow Kyowa to Boost Brand Strength
July 7, 2003
- OTC NEWS IN BRIEF
July 7, 2003
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
